ArticleClinical ophthalmology (Auckland, N.Z.)2021

Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia.

Tyler A Berger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.